Nuclear magnetic resonance metabolic fingerprint of bevacizumab in mutant IDH1 glioma cells

Radiology and Oncology

Carole Marbeuf-Gueye^2¹  Nadia Bouchemal^2²  Claire Banissi^1³  Maja Cemazar^3⁴  Tanja Mesti^1,6⁵  Mohamed N. Triba^2⁶ 

[1] Assistance Publique-Hôpitaux de Paris, Hôpital Avicenne, Service de Neurologie, Bobigny, France^5;CSPBAT, UMR 7244, CNRS, Université Paris 13, Sorbonne Paris Cité, Bobigny, France^2;Department of Experimental Oncology, Ljubljana, Slovenia^3;Division of Medical Oncology, Ljubljana, Slovenia^6;Laboratoire de Recherches Biochirurgicales, paris, France^1;Unité de Biologie Intégrative des Adaptations à l’Exercice, Evry, France^4

关键词: idh1 mutation;    malignant glioma;    bevacizumab;    metabolic;    fingerprint;   

DOI  :  10.2478/raon-2018-0046

学科分类：肿瘤学

来源: Onkoloski Institut Ljubljana / Institute of Oncology Ljubljana

【 摘 要 】

BackgroundMalignant gliomas are rapidly growing tumours that extensively invade the brain and have bad prognosis. Our study was performed to assess the metabolic effects of bevacizumab on the glioma cells carrying the IDH1 mutation, a mutation, associated with better prognosis and treatment outcome. Bevacizumab is known to inhibit tumour growth by neutralizing the biological activity of vascular endothelial growth factor (VEGF). However, the direct effects of bevacizumab on tumour cells metabolism remain poorly known.

【 授权许可】

Unknown